LA JOLLA, Calif.,
Jan. 14,
2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica"
or the "Company") (Nasdaq: CALC), a clinical-stage
biopharmaceutical company focused on developing novel calcium
release-activated calcium (CRAC) channel inhibition therapies for
acute and chronic inflammatory and immunologic illnesses, today
announced the appointment of Alan
Glicklich, M.D. to the Company's Board of Directors
effective on January 15, 2025. Dr.
Glicklich has more than 20 years of experience in the biotechnology
industry and currently serves as Chief Medical Officer of Nuvig
Therapeutics.
"We are very pleased to welcome Alan to our Board and excited to
benefit from his extensive clinical development experience and
impressive track record working with biotech and pharma companies,
specifically in the inflammatory and immunologic disease spaces,"
said Rachel Leheny, Ph.D., Chief
Executive Officer of CalciMedica. "As we progress Auxora towards a
Phase 3 trial in acute pancreatitis and look ahead to data from our
KOURAGE trial in acute kidney injury, Alan's perspective will be
extremely valuable to CalciMedica."
In his position at Nuvig Therapeutics, a company pursuing
multiple inflammatory autoimmune diseases, Dr. Glicklich is
currently leading a clinical team planning to initiate multiple
Phase 2 trials. Prior to Nuvig, Dr. Glicklich was Chief Medical
Officer of Chinook Therapeutics, where he was responsible for the
clinical development, clinical operations, medical affairs,
biometrics, regulatory, and pharmacovigilance teams. While at
Chinook, he designed and operationalized a successful Phase 3
registrational study for atrasentan in IgA nephropathy as well as
multiple earlier phase studies across rare chronic kidney disease
indications. Before that, Dr. Glicklich was Chief Medical Officer
at Bird Rock Bio, where he focused on monoclonal antibody
development for inflammatory and fibrotic diseases. Prior to Bird
Rock, he was Vice President of Clinical Development at Arena
Pharmaceuticals, where he designed and operationalized two Phase 2
programs in pulmonary arterial hypertension and ulcerative colitis.
Dr. Glicklich has also held positions at BMS, Sanofi-Aventis, and
Regeneron. Dr. Glicklich holds an M.D. from the University of Wisconsin and an M.B.A. from the
Emory University-Goizueta School of
Business, as well as a B.A. in Biology from the University of Chicago.
"I am impressed by the data from the multiple Phase 2 clinical
trials with CalciMedica's drug, Auxora, which has shown a variety
of benefits, including a substantial reduction in organ failure, in
acute inflammatory diseases. These benefits are important to
patients in CalciMedica's lead indications of acute pancreatitis
and acute kidney injury, in which organ failure is a
significant cause of mortality and morbidity, no disease-modifying
therapies are available, and the standard of care is inadequate. I
look forward to working with the team at CalciMedica to bring these
much-needed therapies to patients," said Dr. Glicklich.
About CalciMedica
CalciMedica is a clinical-stage
biopharmaceutical company focused on developing novel CRAC channel
inhibition therapies for inflammatory and immunologic
diseases. CalciMedica's proprietary technology targets
the inhibition of CRAC channels to modulate the immune response and
protect against tissue cell injury, with the potential to provide
therapeutic benefits in life-threatening inflammatory and
immunologic diseases for which there are currently no approved
therapies. CalciMedica's lead product candidate Auxora™
has demonstrated positive and consistent clinical results in
multiple completed efficacy clinical trials. CalciMedica has
announced data for a Phase 2b trial
(called CARPO – NCT04681066) in patients with acute
pancreatitis (AP) and accompanying systemic inflammatory response
syndrome (SIRS). The Company has also completed a Phase 2 trial
(called CARDEA – NCT04345614) in patients with COVID
pneumonia. The Company is currently conducting a Phase 2 trial
(called KOURAGE – NCT06374797) in patients with acute kidney
disease (AKI) with associated acute hypoxemic respiratory failure
(AHRF) with data expected in 2025 and continuing to support the
ongoing Phase 1/2 trial (called CRSPA – NCT04195347) in
pediatric patients with asparaginase-induced pancreatic toxicity
(AIPT) with data expected in 2025. CalciMedica was
founded by scientists from Torrey Pines Therapeutics and
the Harvard CBR Institute for Biomedical Research, and is
headquartered in La Jolla, CA. For more information,
please visit www.calcimedica.com.
Forward-Looking Statements
This communication contains
forward-looking statements which include, but are not limited
to, CalciMedica's ongoing and planned clinical trials and the
timing and design thereof, including its plans to progress a Phase
3 trial of Auxora in AP, and the expected timing for the release of
data from those trials, including its ongoing Phase 1/2 CRSPA trial
of Auxora in pediatric patients with AIPT and its ongoing Phase 2
KOURAGE trial of Auxora in AKI with associated AHRF; the potential
benefits of Auxora for the treatment of AP, AKI and AIPT; and the
potential of CalciMedica's proprietary technology to provide
therapeutic benefits in life-threatening inflammatory and
immunologic diseases. These forward-looking statements are subject
to the safe harbor provisions under the Private Securities
Litigation Reform Act of 1995. CalciMedica's expectations and
beliefs regarding these matters may not materialize. Actual
outcomes and results may differ materially from those contemplated
by these forward-looking statements as a result of uncertainties,
risks, and changes in circumstances. Risks and uncertainties that
could cause actual outcomes and results to differ materially from
those contemplated by the forward-looking statements are included
under the caption "Risk Factors" in CalciMedica's Quarterly Report
on Form 10-Q for the quarter ended September
30, 2024, filed with the U.S. Securities and Exchange
Commission (SEC) on November 13,
2024, and elsewhere in CalciMedica's subsequent reports on
Form 10-K, Form 10-Q or Form 8-K filed with the SEC from time to
time and available at www.sec.gov. These documents can be accessed
on CalciMedica's web page at
ir.calcimedica.com/financials-filings/sec-filings. The
forward-looking statements contained herein are made as of the date
hereof, and CalciMedica undertakes no obligation to update them
after this date, except as required by law.
CalciMedica Contact:
Investors and Media
Argot Partners
Sarah Sutton/Kevin Murphy
calcimedica@argotpartners.com
(212) 600-1902
View original content to download
multimedia:https://www.prnewswire.com/news-releases/calcimedica-announces-appointment-of-dr-alan-glicklich-to-board-of-directors-302349872.html
SOURCE CalciMedica, Inc.
